Friday, July 10, 2026

pharma · Advanced Malignant Tumors · Metastatic Pancreatic Ductal Adenocarcinoma

Akeso

Akeso clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

CN HQ
2012 Founded
112 Employees
NMPA registrant Type
Company details
Intelligence · Clinical Programs

Akeso projects

3 ClinicalTrials.gov programs sponsored by Akeso.

Akeso has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. AK104

    Akeso

    Advanced Malignant Tumors

    phase 2 small molecule active

    1 trial
  2. AK112-210

    Akeso

    Metastatic Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial
  3. AK120 or placebo- Part 1- Cohort 1

    Akeso

    Atopic Dermatitis

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Akeso have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.